Korean Post-marketing Surveillance for Orencia
Latest Information Update: 09 Dec 2018
At a glance
- Drugs Abatacept (Primary)
- Indications Juvenile rheumatoid arthritis; Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
- 28 Nov 2018 Results (n=341) evaluating DAS28-P as a predictor of the European League Against Rheumatism (EULAR) response to abatacept in patients with RA, published in The Patient - Patient-Centered Outcomes Research.
- 08 Nov 2017 Results (n=341) assessing DAS28P as a predictor of EULAR response to abatacept in patients with RA, were presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting.
- 08 Mar 2016 Status changed from recruiting to completed as per ClinicalTrials.gov record.